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Abstract 
More than a decade after a Nobel Prize was awarded for discovery of the ubiquitin-proteasome 
system and clinical approval of proteasome and ubiquitin E3-ligase inhibitors, first-generation 
deubiquitylating enzyme (DUB) inhibitors are now approaching clinical trials. However, although our 
knowledge of the physiological and pathophysiological roles of DUBs has evolved tremendously, the 
clinical development of selective DUB inhibitors has been challenging. Here, we discuss these issues 
and highlight recent advances in our understanding of DUB enzymology and biology, as well as 
technological improvements, that have contributed to the current interest in DUBs as therapeutic 
targets in diseases ranging from oncology to neurodegeneration. 
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Introduction 
The sequential enzymatic processes that covalently attach ubiquitin, a 76-residue polypeptide, to 
target proteins – a process known as ubiquitylation - are now well understood (Figure 1a)1. In some 
cases, a single ubiquitin is attached to the target protein, while in others, multiple mono-ubiquitin 
adducts are conjugated to different residues of the target. In many instances, various types of 
ubiquitin chains are produced, wherein one ubiquitin moiety is attached to a free amino group of 
another. This leads to linear ubiquitin chains and chains involving internal ubiquitin lysine residues K6, 
K11, K27, K29, K33, K48, K63, as well as mixed ubiquitin chains containing different linkages, or 
linkages between ubiquitin and ubiquitin-like proteins (Ubls) that include SUMO (small ubiquitin-like 
modifier) and NEDD8 (neuronal-precursor-cell-expressed developmentally downregulated protein-8).  
 
These different types of ubiquitin/Ubl modifications, sometimes referred to as “the ubiquitin code”, 
have specific and diverse effects on protein and cell physiology. For example, such modifications can 
target proteins that are damaged, improperly folded, or have intrinsically short half-lives for 
degradation via the ubiquitin-proteasome system (UPS)2. Here, appropriately polyubiquitylated 
proteins are recognized and degraded by the 26S macromolecular proteasome complex3 via 
mechanisms that have been extensively reviewed elsewhere4,5. In other instances, ubiquitylation 
regulates protein interactions, localisation and enzymatic activities, thereby affecting cellular 
processes including transcription, DNA-damage signalling and DNA repair, cell cycle progression, 
endocytosis, apoptosis and various others6-9. Such control mechanisms often involve ubiquitin-binding 
proteins, many of which exist in eukaryotic cells10. The recent demonstration of post-translational 
modification of ubiquitin itself provides an additional layer of regulation that impacts on various 
cellular processes11. 
 
Like other posttranslational modifications, ubiquitylation is reversible, with peptidases termed 
deubiquitylating enzymes (DUBs) cleaving ubiquitin from substrate proteins, editing ubiquitin chains 
and processing ubiquitin precursors12. Some DUBs and related enzymes are involved in editing or 
processing Ubls and their conjugates13; prime examples of these being the SENP (sentrin/SUMO-
specific protease) proteins that process SUMO precursors and SUMO-conjugates14. DUBs are classified 
into six families based on sequence and domain conservation (Figure 1b): USPs (ubiquitin specific 
proteases), UCHs (ubiquitin COOH- terminal hydrolases), MJDs (Machado-Josephin-domain containing 
proteases), OTUs (ovarian tumour proteases), MINDY (motif interacting with ubiquitin-containing 
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novel DUB family) and JAMMs (JAB1/MPN/MOV34 family). SENPs and the first five DUB families are 
cysteine peptidases, while JAMMs are zinc metallo–peptidases. 
 
Ubiquitylation and related processes control myriad aspects of human cell biology and physiology, and 
defects in such processes contribute to many diseases. Accordingly, DUB deregulation contributes to 
various sporadic and genetic disorders. Notable examples include: the UCH family member BAP1, 
mutated in melanoma, mesothelioma and renal-cell carcinoma15; USP6, translocated in aneurysmal 
bone cysts16; USP7, mutated in neurological disorders17; USP8 whose mutations cause Cushing’s 
disease (CD)18,19; USP9X, whose mutations produce developmental disorders20 and whose expression 
is dysregulated in cancer21; USP15, amplified in certain glioblastoma, breast and ovarian cancers22; and 
CYLD, commonly mutated in cylindromatosis23. Deregulation of MJD family DUBs has also been linked 
to diseases associated with polyglutamine amplification. For example, expansion of DNA "CAG" 
trinucleotide repeats in ATAXIN-3 (ATXN3) causes Machado-Joseph disease24.  Furthermore, 
mutations in the JAMM family member AMSH (STAMBP) cause microcephaly-capillary malformation 
syndrome25. 
 
There has been growing interest in exploiting components of the ubiquitylation machinery as 
therapeutic targets26. While there has been strong progress in developing small-molecule inhibitors of 
ubiquitin/Ubl E1 enzymes27 , the highly pleiotropic nature of E1s means that such drugs will likely be 
confined to acute settings, such as in the treatment of aggressive cancers. Given their greater numbers 
and diversity, E2s, E3s and DUBs offer the potential for developing drugs with more specific effects. In 
particular, being a group of diverse enzymes with well-defined catalytic clefts, DUBs are intrinsically 
attractive as potential drug targets26. However, as we discuss further below, until recently the 
development of selective DUB inhibitors has been limited by insufficient understanding of DUB 
biology, difficulties in establishing robust biochemical assays suitable for compound screening, 
limitations in cellular and in vivo models to assess DUB activity or inhibition, and the pleiotropic nature 
of various small-molecule DUB inhibitors. With many of these issues now being largely overcome, the 
rate of progress of DUB drug discovery has quickened over the past few years, with various selective 
compounds being described and characterized by both academic groups and companies. 
 
In this review, we discuss how DUBs and their deregulation impact on human disease, particularly 
cancer, neurodegeneration and inflammation (Table 1), and highlight the therapeutic potential for 
pharmacological modulation of DUB activities. Recent advances in assay development and screening 
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technologies, which are enabling researchers and drug developers to overcome recurrent challenges 
in the clinical translation of DUB inhibitors, are also discussed. 
 
DUBs in oncology  
Accumulating evidence implicates DUBs in tumorigenesis at multiple levels (Figure 2). First, DUBs such 
as BAP1, UCHL1 and CYLD have been described as displaying intrinsic oncogenic or tumour suppressor 
activities28. Second, some DUBs such as USP22 are connected to controlling key epigenetic changes 
that promote tumour development29. Third, through their deubiquitylating activities, various DUBs, 
such as USP7 and USP28 have been reported to regulate the levels and/or activities of various 
oncogene or tumour suppressor proteins30,31. Fourth, DUBs modulate other therapeutically relevant 
cellular components and processes, such as the ubiquitin proteasome system (e.g. USP14 and 
UCHL5)32, stem-cell renewal (e.g. USP16 or USP22)29,33, DNA-damage responses and repair (e.g. USP1, 
USP11)9, immuno-oncology (e.g. USP7)34, or receptor tyrosine kinases (e.g. USP8, USP9X)35,36. 
Consequently, and as described in more detail below, various DUBs are emerging as attractive targets 
for the development of novel cancer therapies.   
 
Proteasomal DUBs 
The successful targeting of the proteasome for cancer therapy is underlined by the clinical success of 
Bortezomib, a broadly acting proteasome inhibitor, in refractory multiple myeloma37 or mantle cell 
myeloma38. However, three DUBs associated with proteasome functions, POH1, USP14 and UCHL5 
(UCH37), may represent more specific anticancer targets. To facilitate the degradation of proteasome-
targeted substrates, these specialised DUBs remove ubiquitin moieties that would otherwise impede 
entry into the 20S proteasome catalytic core39.  
 
The JAMM metallo-protease POH1 has been highlighted as a potential therapeutic target through 
studies showing that its levels inversely correlate with survival of multiple myeloma patients and that 
its depletion impairs proliferation of multiple myeloma cells40.  In addition, nuclear POH1 is elevated 
in hepatocellular carcinomas and correlates with E2F1 overexpression and tumour growth41.  POH1 
has also been reported to regulate the ubiquitylation and stability of the oncogene, receptor tyrosine 
kinase ERBB242. Furthermore, as POH1 has been connected to promoting cellular responses to DNA 
double-strand breaks, particularly by the process of homologous recombination, POH1 inhibition 
could potentially sensitise cancer cells to DNA-damaging agents and/or preferentially kill cancer cells 
that rely strongly on homologous recombination43.  
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Another potential anticancer therapeutic target is USP14, which is primarily associated with the 
proteasome 19S regulatory particle, where it potentiates ubiquitin recycling44. USP14 is not 
constitutively active but reversibly associates with the 19S RPN1 subunit, which enhances its activity45. 
USP14 inhibits proteasomal degradation of ubiquitin-protein conjugates by trimming ubiquitin chains 
on protein substrates prior to their degradation46. USP14 expression is upregulated in non-small cell 
lung cancer, especially in adenocarcinoma47, and its levels are reportedly elevated in ovarian cancer 
samples48. In line with this, USP14 is connected with several important signalling pathways, for 
example as a substrate of AKT that mediates intracellular signalling for growth factors49 and a 
modulator of dishevelled, a key positive regulator of Wnt signalling50.  
 
Like USP14, the DUB UCHL5 reversibly interacts with the proteasome51, binding to the RPN13/ADMR1 
receptor52 in a manner that enhances UCHL5 isopeptidase activity51,53. A key function of UCHL5 is to 
remove distal ubiquitin moieties from polyubiquitylated proteins, thereby liberating proteins from 
destruction54, or facilitating destruction of certain substrates, as described for inducible nitric oxide 
synthase and IκB-α55. It therefore appears that, like USP14, UCHL5 suppresses the destruction of 
certain proteins, while promoting degradation of others. Notably, RNA interference studies showed 
that depletion of either USP14 or UCHL5 alone had no detectable effect on cell growth, proteasome 
structure or proteolytic capacity, but did accelerate cellular protein degradation53. By contrast, 
depletion of both DUBs decreased protein degradation, suggesting that they have overlapping 
functions. UCHL5 is over-expressed in epithelial ovarian cancer, which is associated with advanced 
tumour progression and poor clinical outcome56. UCHL5 is also over-expressed in hepatocellular 
carcinoma, and was shown to promote cell migration and invasion57.  
 
These proteasome-associated DUBs represent attractive drug targets, as their inhibition might have 
substantial effects on cancer-cell physiology but with fewer toxicities than are seen with drugs 
targeting core proteasome catalytic function58. Indeed, VLX1570 (Table 2), the most advanced 
reported DUB inhibitor, which was recently in Phase I trials (now suspended) for treatment of multiple 
myeloma and solid tumours59, has been described to target USP14 and UCHL560. VLX1570 is a ring-
expanded version of the compound b-AP15 (VLX1500) identified from cell-based screens looking for 
compounds inducing p53-independent apoptosis. Cells treated with b-AP15 accumulate polyubiquitin 
chains61, and it has been claimed that b-AP15 targets USP14 and possibly also UCHL560. This compound 
was reported to be reversible and reasonably selective against other DUBs60 in a cell-based activity 
probe assay, with an IC50 of ~2 µM against purified 19S proteasome DUB activities. b-AP15 has strong 
activity when tested in various in vivo solid tumour models59, including multiple myeloma62, but it 
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remains to be seen whether VLX1570 selectivity will be sufficient to deliver on its promise as a next-
generation proteasome inhibitor. Cleave Biosciences has also published a series of patent applications 
describing compounds that inhibit JAMM proteases, providing potential angles for developing 
selective POH1 inhibitors (Table 2)63-65. 
 
DUBs linked to DNA repair 
One hallmark of cancer is the down-regulation, loss or deregulation of certain DNA repair and DNA-
damage response (DDR) pathways and/or strong reliance on such pathways66,67.  DNA repair and DDR 
mechanisms are regulated by post-translational modifications, such as ubiquitylation, with many DUBs 
strongly linked to such processes9,68.  
 
One example of this is USP1, a DUB identified as a regulator of FANCD2 ubiquitylation, a key protein 
involved in the Fanconi anemia (FA) pathway of DNA crosslink repair69,70. USP1 influences 
accumulation of the FA core complex at DNA-damage sites and deubiquitylates FANCD2/FANCI in a 
cell-cycle dependent manner69. USP1 also removes mono-ubiquitin from PCNA, a DNA-replication 
component that also functions in DNA repair by translation synthesis71. Other USP1 activities include 
functioning in a feedback loop to limit DDR CHK1 protein kinase activity72 and regulating cellular 
differentiation in osteosarcoma cells by deubiquitylating and hence affecting the stability of ID 
(inhibitors of DNA binding) proteins73. In vitro, USP1 activity is greatly stimulated by UAF1 (WDR48), 
enhancing USP1 catalytic turnover (kcat) but not affinity (Km) for mono-ubiquitylated substrates74. 
Selective USP1 inhibitors with sub-micromolar potency have been identified75, with one, pimozide, 
shown to re-sensitise platinum-resistant non-small lung cancer cells and promote FANCD2 and PCNA 
mono-ubiquitylation75. However, while these studies indicated on-target effects, DUB selectivity 
profiling suggested that pimozide might be less selective than initially described76. Optimisation of 
certain USP1 screening hits has generated additional molecules77, most notably a selective pyrimidine-
core compound, ML323 (Table 2). This molecule allosterically blocks complex formation between 
UAF1 and USP178, potentiates cisplatin cytotoxicity and increases PCNA and FANCD2 mono-
ubiquitylation in cells77. So far, however, little progress has been made in advancing selective USP1 
inhibitors into clinical development.  
 
Another DUB linked to DNA repair is USP11, which was initially described to complex with the DDR 
tumour suppressor BRCA2 to promote the DNA double-strand break repair pathway of homologous 
recombination79. Depletion of USP11 has been shown to sensitize cells to AZD2281/olaparib, which 
inhibits the DDR enzyme PARP80. Recently, an interaction between BRCA1 and PALB2 – which 
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functionally cooperate with BRCA2 in DNA repair – was shown to be under ubiquitin control, with 
PALB2 ubiquitylation suppressing its interaction with BRCA1 in a manner counteracted by USP1181.  
The only currently reported USP11 inhibitor is the topoisomerase inhibitor mitoxantrone (Table 2)82. 
While the authors reported low nanomolar potency in a pancreatic ductal adenocarcinoma cell 
survival model, no further development of this compound has been reported. Given the apparent 
amenability of USP11 to small-molecule inhibition, it is notable that USP4, a DUB closely related to 
USP11, was recently shown to play important roles in the DDR via promoting early stages of 
homologous recombination83.  
 
USP9X21, which maintains DNA replication-fork stability and DNA-damage checkpoint responses by 
regulating the protein CLASPIN during S-phase84, may represent another potential therapeutic target. 
USP9X has been shown to affect radiosensitivity in glioblastoma cells by MCL1-dependent and -
independent mechanisms85. The best-described USP9X inhibitor is WP1130 (Table 2), identified in a 
screen for JAK2 inhibitors, which was shown to inhibit USP9X as well as other DUBs (USP5, USP14 and 
UCHL5)86,87. The covalent mechanism-of-action of this compound was shown via mass spectrometry 
to be reversible76. 
 
Regulation of oncogenes and tumour suppressors 
Various DUBs have been reported to have connections to tumour suppressor or oncogenic functions, 
and may therefore represent potential therapeutic targets88.  
 
p53 regulation: Several DUBs have been linked to regulation of the tumour suppressor protein p53, 
which plays pivotal roles in cellular stress responses and is lost or mutated in many cancers89. Human 
HDM2 is a RING-type ubiquitin E3 ligase and key negative regulator of p53, via its ability to ubiquitylate 
p53 and target it for degradation90. By cleaving ubiquitin chains on HDM2 (or its mouse counterpart 
MDM2), USP7 counteracts HDM2 proteasomal degradation, leading to p53 suppression through 
increased ubiquitylation and degradation91,92. In theory, therefore, USP7 inhibition should trigger 
HDM2 degradation, p53 stabilisation and ultimately activation of apoptotic pathways in tumour 
cells93. Additional USP7 targets have also been described, such as PTEN, FOXO4 and FOXP334,94,95, 
suggesting alternative therapeutic mechanisms for USP7 inhibitors. USP7 has also recently been 
shown to promote DNA replication via acting as a deubiquitylase for the Ubl, SUMO96. 
 
The first published sub-micromolar USP7 inhibitor, HBX4110897, was shown to be a rather non-specific 
inhibitor of DUBs76. Recently, more selective amidotetrahydroacridine derivatives such as HBX19818 
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and HBX28258 were identified, although these exhibited fairly low potency98. Despite this, HBX19818 
was shown to covalently bind the USP7 catalytic Cys in preference to other cysteinyl groups, and to 
stabilise p53 and promote G1 arrest and apoptosis in cells98. Progenra’s thiophen chemical series also 
provided relatively non-specific USP7 inhibitors, including the compounds P5091 and P2207799. In 
multiple myeloma cells, P5091 stabilised p53 and inhibited tumour growth, while in animal models, 
P5091 was well-tolerated, inhibited tumour growth, and prolonged survival99. More recent in vivo 
studies using P22077 within an orthotopic neuroblastoma mouse model showed significant inhibition 
of xenograft growth100. While these findings are encouraging, little is known about the binding modes 
of these compounds and whether they can be further optimised into more “drug like” entities. 
Recently, Almac Discovery and Genentech reported that fragment-based screens provided hits as 
starting points for USP7 discovery programmes101. Optimisation of one hit, ADC-01, assisted by X-ray 
crystallography, produced the non-covalent, highly selective USP7 inhibitor ADC-03 (Table 2). 
 
The stability of p53 has also been recently reported to be regulated by the DUB, ATXN3102.  ATXN3 was 
shown to bind and deubiquitylate p53, resulting in p53 stabilisation. Deletion of ATXN3 resulted in 
destabilisation of p53, while ectopic expression of ATXN3 induced expression of p53 target genes and 
promoted p53-dependent apoptosis. How and whether ATXN3 inhibitors could be exploited to treat 
cancer or other diseases remains to be established. 
 
USP28 is another DUB that has recently been connected to p53, which functions together with the 
protein 53BP1 to promote p53-mediated transcriptional responses103. Furthermore, USP28 is mutated 
in human cancer cells, and is reported to antagonise the tumour suppressor FBW731, highlighting the 
potential for USP28 inhibitors in various cancers, especially colorectal104. USP28 is also reported to 
antagonise ubiquitin-dependent degradation of the oncogene product MYC as well as c-JUN and 
NOTCH105. While no USP28 inhibitors have yet been reported, it seems likely that drug-discovery 
activities are underway. 
 
HIF1α and USP20: Another tumour suppressor protein, which has been linked to DUB activity, is 
the von Hippel-Lindau tumour suppressor protein (pVHL), which ubiquitylates hypoxia-inducible 
factor 1α (HIF1α) when cellular oxygen levels are normal, leading to the degradation of HIF1α. USP20, 
also known as VHL protein-interacting deubiquitinating enzyme 2 (VDU2), is reported to 
deubiquitylate a number of proteins, including HIF1α. USP20-mediated deubiquitylation of HIF1α 
prevents proteasomal degradation, allowing for transcription of hypoxic response genes. Thus, 
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inhibition of USP20 has potential for suppressing proliferation of hypoxic tumour cells. GSK presented 
brief details of its search for USP20 inhibitors at a conference in 2012 (Table 2)106. 
 
 
EGFR and USP8: Ubiquitylation serves as a signal that delivers membrane receptors from the cell 
surface to lysosomes, and in mammalian cells this has been most intensively studied for epidermal 
growth factor receptor (EGFR). Upon EGF binding, activated EGFR is rapidly internalized and 
transported, via early and late endosomes, to lysosomes where EGFR is degraded. USP8, also known 
as UBPY, deubiquitylates EGFR on early endosomes, rescuing EGFR from degradation107,108.  In several 
cancers, including lung, breast and glioblastoma, EGFR is amplified or mutated in the tyrosine kinase 
domain, resulting in deregulation of receptor signalling that drives uncontrolled proliferation of 
tumour cells109. USP8 inhibitors (e.g. HBX90659) of a similar structural class to those identified for 
USP7110 have been reported (Table 2). Moreover, a derivative of these compounds was shown to be 
efficacious in mouse models of lung cancer111. 
 
TGF-β and USP15: USP15 regulates the TGF-β (transforming growth factor beta) pathway and is 
believed to be important for the proliferation of glioblastoma cells22. USP15 binds to the SMAD7–
SMAD E3 ligase complex and deubiquitylates and stabilises the type I TGF-β receptor, leading to 
enhanced TGF-β signalling.  The USP15 gene is amplified in glioblastoma, breast and ovarian cancers, 
and high expression of USP15 correlates with high TGF-β activity22. Depletion of USP15 reduces the 
oncogenic capacity of patient-derived glioma-initiating cells due to the diminished TGF-β signalling, 
suggesting therapeutic potential for development of USP15 inhibitors.  In addition, USP15 has been 
shown to deubiquitylate receptor-activated SMADs (R-SMADs)112, another set of TGF-β signalling 
pathway components. 
 
Other oncogenic DUBs: The DUB UCHL1, normally expressed only in neurons and neuro-endocrine 
tissues113,114, is highly expressed in many cancers, with its expression correlating with poor 
prognosis115. While there are reports that UCHL1 has a tumour suppressive role, most evidence 
supports its role as an oncogene115. Indeed, in a transgenic mouse model with constitutively activated 
UCHL1, sporadic tumours developed in many tissues116. Moreover, in vitro tumorigenesis studies 
showed that UCHL1 expression stimulated oncogenesis and an invasive phenotype117-119, while UCHL1 
depletion had anti-tumour effects and blocked cell migration in a lung cancer cell line117. The precise 
mechanism by which UCHL1 contributes to tumorigenesis remains unclear, although reports suggest 
that it contributes to cell survival signalling, cell cycle regulation, DNA repair, and regulating pools of 
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free ubiquitin in ways that affect protein degradation and function115. UCHL1 inhibitors have been 
described, the most potent being isatin acyl-oximes (LDN-57444, Table 2) with some selectivity over 
UCHL3120. In addition, a series of pyridinones have been identified as moderate UCHL1 inhibitors121. 
Enzyme kinetic studies revealed that these compounds are uncompetitive inhibitors and are selective 
for UCHL1, exhibiting no inhibition of other cysteine hydrolases tested. A weak tripeptide fluoromethyl 
ketone (FMK) inhibitor was subsequently shown through crystallographic studies to bind within the 
UCHL1 active site, irreversibly modifying the active-site cysteine122.  Mission Therapeutics has also 
developed several series of potent and selective UCHL1 inhibitors123,124. While no UCHL1 inhibitors 
have demonstrated anti-tumour activity in vivo, inducible depletion of UCHL1 has been shown to 
cause disease regression in an orthotopic multiple myeloma model125. 
 
Another DUB associated with oncogenesis is USP22, the catalytic subunit of a deubiquitylase module 
in the SAGA (Spt-Ada-Gcn5-acetyltransferase) complex. The best-characterised substrates for SAGA 
include several acetylation sites in histone H3 and a ubiquitylation site in histone H2B, post-
translational modification of which regulates gene expression29. USP22 has strong links to 
oncogenesis29, having been identified in microarray screens as part of an 11-gene ‘death from cancer’ 
signature for highly aggressive, therapy-resistant tumours. USP22 was later shown to act as an 
oncogene product, regulating cell cycle progression, proliferation and apoptosis126. Increased 
expression of USP22 has been connected with poor prognosis in several cancers including liver127, 
colorectal127, breast128, oesophageal squamous-cell carcinoma129 and oral squamous-cell carcinoma130. 
If USP22 DUB activity can be linked to survival and progression of these cancers, then inhibitors may 
provide attractive prospects for new therapies. 
 
Cancer immunotherapy 
Given the role of ubiquitin modifications and DUBs in many inflammatory processes (see below) as 
well as the renewed interest in targeting the immune system to fight cancer, the anti-neoplastic 
potential of therapeutically inhibiting DUBs involved in the immune system is being investigated. 
Amongst these is USP7, which positively regulates the stability of FOXP3, a critical transcription factor 
controlling the differentiation of regulatory T cells (Treg)34. In a search for DUBs that contribute to 
GATA3 stabilisation in Foxp3-expressing cells, both USP7 and USP21 were shown to upregulate 
GATA3-mediated activity using a reporter assay131. Furthermore, depletion of USP21 in Treg cells 
resulted in downregulation of FOXP3, compromised expression of Treg signature genes and impaired 
their suppressive activity132. As Treg cells restrict anti-tumour immune responses and promote tumour 
survival133, these results suggest that depletion of FOXP3 in Treg cells by targeting USP7 and USP21 
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offer promise for anti-cancer immunotherapies. In this regard, Mission Therapeutics is investigating 
USP7 as an immuno-oncology target and has developed USP7 inhibitors (Mission Therapeutics 
Pipeline available from:  http://missiontherapeutics.com/programmes/). 
 
DUBs in neurodegenerative disease 
Identification of ubiquitin in protein aggregates associated with neurodegenerative pathologies such 
as neurofibrillary tangles in Alzheimer’s disease, Lewy bodies in Parkinson’s disease or intranuclear 
inclusions in heridetary polyglutamine expansion disorders, has prompted much interest in 
understanding how ubiquitylation and deubiquitylation affect such aggregates134. DUB function in the 
central nervous system has been described in detail elsewhere135,136, therefore below we focus on a 
select number of DUBs connected to neurodegenerative disease. 
 
Mitochondrial quality control 
Mitochondrial dysfunction and UPS impairment have been described as hallmarks of aging137, and 
have been implicated in the etiopathogenesis of many age-related diseases, particularly 
neurodegenerative disorders such as Alzheimer’s and Parkinson’s. In accord with this connection, 
ubiquitylation has close links to mitochondrial function, with the UPS maintaining mitochondrial 
homeostasis by regulating organelle dynamics, the mitochondrial proteome and mitophagy138. 
Conversely, mitochondrial dysfunction can impair cellular protein homeostasis by generating oxidative 
damage. Notably, mutations in the ubiquitin E3 ligase Parkin are causally associated with certain cases 
of familial Parkinson’s disease139. As Parkin ubiquitylates mitochondrial components, thus promoting 
turnover of mitochondria by lysosome-mediated mitophagy, defective mitophagy and accumulation 
of defective mitochondria that cause enhanced oxidative stress could be an underlying cause of 
Parkinson’s disease140,141. A corollary of this is that Parkin activation – or inhibition of factors 
counteracting Parkin – could provide opportunities for disease alleviation.  
 
A screen for DUBs that oppose Parkin function identified the mitochondrial-associated DUB USP30 as 
an antagonist of Parkin-mediated mitophagy142,143, with USP30 depletion significantly decreasing 
mitochondrial numbers in cells, a phenotype that was rescued by wild-type but not catalytically 
inactive USP30. Furthermore, USP30 depletion in vivo provided stress protection in Drosophila 
melanogaster models of Parkinson’s disease (park25 or pink1B9). In line with such findings, USP30 
depletion in human HeLa cells led to elongated and interconnected mitochondria144, suggesting a role 
for USP30 in regulating mitochondrial fusion/fission. Current models invoke USP30 functioning under 
normal physiological conditions to prevent inappropriate mitophagy. However, in response to stresses 
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such as membrane depolarization, Parkin is recruited to mitochondria to promote mitophagy145. 
Accordingly, under conditions of mitochondrial dysfunction – such as are caused by defects in Parkin 
(or its positive regulator PINK1), USP30 is thought to counteract clearance of damaged mitochondria, 
leading to a build-up of metabolically and energetically deficient cells142. It is thus hypothesised that, 
in the context of certain mitochondrial dysfunctions, USP30 inhibition would have therapeutic 
benefits. So far, only one chemical inhibitor of USP30 has been described, 15-oxospiramilactone (Table 
2), which induced mitochondrial elongation in Mfn1-knockout mouse fibroblasts, with no effect on 
cell viability146. Mission Therapeutics is exploring USP30 inhibition for the treatment of Parkinson’s 
disease and other mitochondrial disorders, and has published several patent applications describing 
USP30 inhibitors124,147. 
 
Two other DUBs connected to mitophagy are USP8 and USP15. Notably, USP8 depletion was found to 
delay Parkin translocation onto depolarized mitochondria, as well as mitochondrial clearance, and 
USP8 displayed an ability to remove K6 ubiquitin chains from Parkin in vitro148.  In addition, USP8 has 
been shown to remove ubiquitin K63 chains from -synuclein149, a protein known to aggregate, often 
in a ubiquitylated form, in neuronal inclusion bodies (Lewy bodies) associated with neurodegenerative 
diseases such as Parkinson’s disease. Depletion of USP8 in either human cells or Drosophila resulted 
in increased lysosomal degradation of α-synuclein149. Meanwhile, USP15 was identified as a Parkin-
interacting protein that co-localizes with mitochondria150. In cells over-expressing Parkin, over-
expression of wild-type but not catalytic-dead USP15 strongly inhibited mitophagy143,150. Furthermore, 
depleting endogenous USP15 enhanced mitophagy in HeLa cells, in a human dopaminergic neuronal 
cell line and in primary fibroblasts from human patients150. USP15 does not deubiquitylate Parkin 
under basal conditions or when cells are treated with mitochondrial depolarizing agents. It also does 
not appear to affect Parkin translocation to mitochondria150, although it can oppose Parkin-mediated 
mitochondrial ubiquitylation. Finally, USP15 loss in Drosophila was found to rescue both locomotor 
defects and accumulation of dysfunctional mitochondria in flight muscles of parkin knock-out flies143. 
Collectively, these findings highlight the potential for USP8 and USP15 inhibitors in Parkinson’s disease 
and perhaps other diseases associated with mitochondrial dysfunction. 
 
Further highlighting connections between Parkinson’s disease and DUBs, ATXN3 has been shown to 
interact with Parkin in a manner that counteracts Parkin auto-ubiquitylation151.  In addition, USP7 was 
recently shown to remove K63-linked ubiquitin chains from -synuclein149, a protein that aggregates 
and accumulates in Lewy bodies, which are hallmarks of Parkinson’s disease.  
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USP14  
As described above, USP14 removes ubiquitin from certain substrates targeted to the proteasome, 
thus rescuing such substrates from degradation and maintaining free ubiquitin pools54,152. IU1 (Table 
2), a reversible small-molecule USP14 inhibitor, was shown to target the USP14 catalytic site46 and 
promote degradation of several over-expressed proteins whose accumulation is linked to 
neurodegenerative diseases, such as Tau, TDP-43 and ATXN3. Notably, IU1 only promoted degradation 
in Usp14+/+ murine embryonic fibroblasts46 but not in Usp14-/- cells, suggesting that this compound 
functions specifically through USP14. Furthermore, IU1 reduced accumulation of menadione-induced 
oxidized proteins and ameliorated menadione or hydrogen peroxide-induced cell death in human 
HEK293 cells46. Proteostasis Therapeutics (in collaboration with Biogen) is developing USP14 inhibitors 
for the clearance of aggregation-prone proteins, including α-synuclein in Parkinson’s disease and Tau 
in Alzheimer’s disease (http://www.proteostasis.com/product-pipeline/usp14/), and has published 
several patent applications describing USP14 inhibitors153-155. 
 
Despite the growing interest in USP14 as a therapeutic target in cancer and neurodegeneration, the 
fact that its loss causes severe morbidity and postnatal lethality requires further investigation, 
especially in regards to its role in neuromuscular junctions: the neuromuscular phenotype of USP14 
deficient axJ mice is rescued by neuronal-specific expression of USP14156. Furthermore, the extent to 
which USP14 contributes to the clearance of proteins involved in neurodegeneration in vivo remains 
controversial157. The development and use of USP14 inhibitors in disease-relevant models may shed 
further light on such issues, and hopefully will define potential therapeutic windows for USP14 
inhibition in disease settings. 
 
USP16  
Down syndrome is a congenital disorder driven by triplication of human chromosome 21, on which 
the USP16 gene resides. USP16 has been reported to regulate cell-cycle progression and gene 
expression through deubiquitylation of histone H2A158. Defects in haematopoietic stem-cell self-
renewal in a Down syndrome mouse model were rescued by reducing USP16 expression to levels 
similar to those in control mice159. In addition, USP16 over-expression in normal human fibroblasts 
and neural progenitors lead to reduced cell expansion159, similar to the strong proliferation defects 
observed in human Down syndrome fibroblasts160. Thus, USP16 is a key regulator that controls stem 
cell self-renewal and senescence in Down syndrome, suggesting that inhibitors of USP16 might 
provide therapeutic benefits to such individuals. 
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DUBs in immunity and inflammation 
Pathogens are recognised by several families of pattern-recognition receptors (PRR), and activate 
various signal-transduction cascades via the retinoic acid–inducible gene 1–like receptor (RLR), 
nucleotide-binding oligomerization domain-like receptor (NLR) and the toll-like receptor (TLR)161.  
These signalling events mediate induction of inflammation that is important for recruiting immune 
cells to sites of infection.  Ubiquitylation is a critical post-translational modification in this process161.  
Non-degradative K63- and M1-linked ubiquitin chains mediate the key upstream event of recruiting 
the TGF-activated kinase (TAK1) and the IB kinase (IKK) complexes, respectively162. K63 
polyubiquitination activates the TAK1 kinase complex, which phosphorylates IKK at key serine 
residues in the activation loop, resulting in IKK activation and transcriptional activation of target genes 
which include mediators of immune and inflammatory responses as well as feedback inhibitors of the 
NF-kB pathway163.  Negative regulators include DUBs that cleave K63 and linear chains such as A20, 
CYLD and OTULIN (also known as FAM105B or Gumby)161,164,165. 
 
The TNFAIP3 gene, which encodes the A20 protein, is probably the best-characterized DUB linked to 
inflammation166. A20 plays a key role in restricting TLR signalling and maintaining immune homeostasis 
through deubiquitylation of NF-B signalling factors such as NEMO, RIPK1 and TRAF6167. In addition, 
A20 can bind polyubiquitin chains through its zinc finger domain, allowing for interaction with 
ubiquitylated NEMO protein. This ubiquitin-induced recruitment of A20 to NEMO is sufficient to block 
IKK phosphorylation by its upstream kinase TAK1, preventing NF-B activation168. Thus, A20 deficiency 
promotes local or systemic inflammation in vivo, underscoring why inactivating TNFAIP3 mutations 
have connections with both inflammatory and autoimmune syndromes169.  
 
CYLD is another DUB known to negatively regulate ubiquitylation of RIG-1 (one of the major RLRs) and 
RIG-I mediated IFN gene induction170,171.  CYLD binds to RIG-I and inhibits ubiquitylation and signalling 
functions of RIG-I.  CYLD also inhibits the ubiquitylation of TBK1 and IKK which contributes to the 
negative regulation of IFN responses171 Consistently, CYLD deficiency causes constitutive activation of 
TBK1 and IKK in dendritic cells.  Despite enhanced RIG-I signalling, CYLD-deficient cells and mice are 
more susceptible to VSV infection due to attenuated signalling and antiviral gene expression induced 
by IFN, suggesting a positive role for CYLD in regulation of type I IFN receptor function161. 
 
Ubiquitin M1-linked chains are generated by the linear ubiquitin chain assembly complex (LUBAC) 
consisting of HOIP, HOIL-1 and SHARPIN. LUBAC is recruited to many immune receptors, and 
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ubiquitylates target proteins, including RIPK1, RIPK2, MyD88, IRAKs and NEMO172,173. Genetic loss of 
LUBAC components leads to immunodeficiency174 and inflammatory phenotypes in mice175-178, and 
mutations in LUBAC components also cause inflammatory conditions in humans179,180. Hence, loss of 
M1-linked chains imbalances immune signalling.  OTULIN is the only DUB known to specifically cleave 
M1 linkages181,182. Accordingly, a homozygous hypomorphic mutation in human OTULIN has recently 
been shown to cause a potentially fatal auto-inflammatory condition termed OTULIN-related 
autoinflammatory syndrome (ORAS)183. 
 
Similar to ubiquitin, the Ubl ISG15 (interferon-stimulated gene 15) plays a key role in cellular signalling 
in response to pathogens.  Conjugation of ISG15 to various cellular substrates is reversed by the 
interferon (IFN)-inducible isopeptidase USP18. USP18 is upregulated after viral infection, type I and 
type III IFNs, lipopolysaccharide, tumour necrosis factor alpha or genotoxic stress. In addition to its 
isopeptidase activity, USP18 negatively regulates type I and type III IFN signalling by blocking the type 
I IFN receptor 2 subunit184. 
 
Inflammatory and autoimmune disorders  
Debilitating autoimmune diseases range from those with genetic components such as Crohn’s disease, 
diabetes mellitus type 1, Graves disease and rheumatoid arthritis185, to sporadic conditions including 
celiac disease, inflammatory bowel disease, multiple sclerosis, psoriasis, and systemic lupus 
erythematosus. In addition, chronic inflammatory diseases are characterised by a prolonged and 
persistent pro-inflammatory state, and include autoimmune disease as well as metabolic syndromes, 
neurodegenerative disease, chronic obstructive pulmonary disease and cardiovascular disease. 
 
Following PRR stimulation, dendritic cells secrete various cytokines that regulate the differentiation 
of CD4+ T cells to different subsets of helper T (Th) cells, including inducible Treg cells, T follicular 
helper cells, and Th1, Th2, Th9 and Th17 cells186. Th17 cells mediate pro-inflammatory functions 
through the secretion of pro-inflammatory cytokines, including IL-17A, IL-17F, and IL-22187. Moreover 
Th17 cells have been implicated in the development of autoimmune diseases such as multiple 
sclerosis, rheumatoid arthritis and systemic lupus erythematosus 188. 
 
USP4 has been shown to stabilise the nuclear receptor RORt in Th17 activated T cells, and has been 
proposed as a possible therapeutic target for rheumatoid arthritis189. Yang et al., reported that USP4 
is highly expressed in Th17 cells and its depletion resulted in decreased RORt as well as IL-17A 
expression189. In addition, use of the reported USP4 inhibitor Vialinin A (Table 2) also diminished RORt 
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and IL-17A expression190. Furthermore, expression of USP4, IL-17A and IL-17F mRNA have been shown 
to be significantly elevated in CD4+ T cells from rheumatoid arthritis patients compared to healthy 
controls189, providing further evidence for a role of USP4 in rheumatoid arthritis. 
 
TRABID (also known as ZRANB1), is required for TLR-mediated expression of the inflammatory 
cytokines IL-12 and IL-23 in dendritic cells191. TRABID is proposed to deubiquitylate and stabilise the 
histone demethylase, JMJD2D, which regulates histone modification at the Il12 and Il23 promoters to 
facilitate recruitment of the NF-B family member c-Rel191. Conditional deletion of TRABID in dendritic 
cells impairs IL-12 and IL-23 production and the generation of Th1 and Th17 subsets of inflammatory 
T cells, rendering mice refractory to the induction of experimental autoimmune encephalomyelitis 
(EAE)191. 
 
Another DUB associated with the activity of Th17 cells is USP18.  Although this DUB has been 
extensively studied in the context of viral infection, Liu et al., demonstrated that USP18 regulates the 
TAK1-TAB interaction, which is required for Th17 differentiation and autoimmune response192. 
Consistent with this, USP18-deficient mice were resistant to EAE192.  
 
T cell receptor signalling has been shown to be facilitated by the DUB, CEZANNE1 (OTUD7B), which 
binds and deubiquitylates zeta-chain associated protein (ZAP70), thus preventing the interaction of 
ZAP70 with negative-regulatory phosphatases193.  ZAP70 is a cytoplasmic protein tyrosine kinase that 
plays a critical role in T-cell signalling.  ZAP70 is recruited to phosphorylated sites on the T cell receptor 
where it is subsequently phosphorylated by the SRC kinase LCK.  Phosphorylation of ZAP70 is required 
for full activation and downstream phosphorylation of adaptor proteins, which facilitate T cell 
signalling194.  In addition, CEZANNE1 deficient mice exhibit attenuated T cell responses to bacterial 
infection and were refractory to EAE193. While young CEZANNE1 knockout mice had similar naïve and 
memory-like T cells compared to wild-type mice, older mice deficient for CEZANNE1 had reduced IFN-
 producing Th1 cell subsets193. 
 
Similar to Th17 cells, Th1 cells have the capacity to cause inflammation and autoimmune disease.  The 
development, differentiation and function of Th1 cells is driven by the T-box transcriptional factor T-
bet, which promotes Th1 immune response primarily through promoting expression of the cytokine 
IFN-195. The DUB USP10 has been shown to deubiquitylate and stabilise T-bet, resulting in enhanced 
secretion of IFN-196. In addition, USP10 mRNA expression was found to be elevated in PBMCs from 
patients with asthma compared to healthy donors196. 
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While it is currently unclear why so many DUBs are involved in the regulation of immune responses, 
it is possible that different DUBs function in distinct cell types. Many published studies are based on 
cell lines and over-expression systems, and the expression of endogenous DUBs in various immune 
cells will be an important area for future investigation. Similarly, the generation of genetic models and 
the development of inhibitors for Cezanne1, TRABID, USP4, USP10 and USP18 will help determine 
their therapeutic potential. 
 
DUBs with links to infectious diseases 
As described below, there is growing interest in DUBs as potential therapeutic targets for various 
infectious diseases of man and other animals. Such potential is being explored both by developing 
compounds that inhibit the activity of pathogen-encoded DUB-like proteins, or target host-cell DUBs 
that control the pathogen life cycle or infectivity. 
 
Viral infections 
Ubiquitylation is important for modulation of protein–protein interactions, including the activation of 
innate immune signalling pathways, so perhaps not surprisingly, various viruses encode DUBs as a 
strategy to inhibit ubiquitin and ISG15-dependent antiviral pathways197. Severe acute respiratory 
syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are 
two of the six known human coronaviruses. Both are highly pathogenic, with the potential for human-
to-human transmission, and contain papain-like cysteine proteases termed SARS-CoV PLpro and 
MERS-CoV PLpro, respectively. In addition to processing viral polyprotein, these proteases remove 
ubiquitin and ISG15 from host cell factors, resulting in antagonism of the host antiviral immune 
response198. Hence, both SARS-CoV PLpro and MERS-CoV PLpro have been proposed as important 
antiviral targets. The X-ray structures of both proteases have shown similarity to the USP family of 
DUBs199-201. 
 
OTU domain-containing proteases from diverse RNA viruses, including the nairoviruses Crimean-
Congo hemorrhagic fever virus and Dugbe virus, the papain-like protease (PLP2) domain of the 
arterivirus equine arteritis virus, and the protease (PRO) domain of the tymovirus turnip yellow mosaic 
virus can hydrolyze ubiquitin and ISG15 from cellular target proteins197,202. Many positive-strand RNA 
viruses, including arteriviruses and tymoviruses, encode polyproteins that are post-translationally 
cleaved by internal protease domains. In accord with this, both arterivirus PLP2 and tymovirus PRO 
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are critically required for viral replication due to their primary role in polyprotein maturation197. Thus, 
viral OTU proteases may represent promising therapeutic targets. 
 
Bacterial infections 
Bacteria employ a repertoire of effector proteins that target the eukaryotic ubiquitin system to 
promote bacterial pathogenicity. Pruneda et al. have recently characterised protease activity from 
human bacterial pathogens including Salmonella (SseL), Escherichia (ElaD), Shigella (ShiCE), Chlamydia 
(ChlaDUB1), Rickettsia (RickCE), and Legionella (LegCE)203. LegCE showed no proteolytic activity; SseL, 
ElaD, and ShiCE demonstrated ubiquitin-specific protease activity; while ChlaDUB1 and RickCE cleaved 
both ubiquitin and, to a lesser extent, NEDD8-modified peptides. Interestingly, these DUBs encoded 
by human pathogens showed strong preference for K63-linked chains, only targeting K48 and K11 
chains at later time points or higher enzyme concentrations.  Therefore, bacterial DUBs are potential 
therapeutic targets. 
 
Parasitic infections 
In addition to expressing DUBs that target host functions, similar to viruses and bacteria, eukaryotic 
parasites also possess Ubl pathways of their own. The use of ubiquitin-based activity probes to identify 
DUBs in Plasmodium falciparum led to the identification of PfUCH54, which was shown to have 
deubiquitylating activity and also an ability to remove adducts of the Ubl, NEDD8204. Further 
investigation of the parasite Toxoplasma gondii using a similar strategy identified four DUBs, one of 
which was orthologous to mammalian UCHL3205. Structural studies on PfUCHL3 explained the dual 
specificity of the enzyme, and PfUCHL3 was found to be required for parasite survival206. Distinct 
differences in the ubiquitin binding site between PfUCHL3 and its human counterpart suggest that this 
parasitic DUB can be selectively targeted by inhibitors. Based on the above findings, it will be of great 
interest to further explore anti-infective opportunities for DUB inhibitors. 
 
Therapeutic challenges, emerging technologies and compounds 
Despite the significant and growing attractiveness of DUBs as drug targets, DUB-focused drug 
discovery has been challenging, with researchers in this arena facing various obstacles. First, while 
DUBs have clear catalytic pockets that a priori appear suitable for drug development, a key challenge 
has been to identify potent compounds that show selectivity amongst related DUBs and have 
properties commensurate with their development for clinical use. Second, ubiquitylation and 
deubiquitylation are intracellular processes that, at least at present, are only amenable to classical 
small-molecule chemical approaches. Third, because most DUBs execute the transfer of ubiquitin 
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molecules via a reactive thiol group, most standard assays used to identify inhibitors are prone to non-
selective redox or alkylating false positives207. Fourth, the mechanisms-of-action of DUB enzymes are 
often complex, involving regulation of enzymatic activity through allosteric effects and/or substrate-
mediated catalysis, with many DUBs alternating between active and non-active conformations (see 
below)208,209. This makes it challenging both to design predictive biochemical assays and develop drug-
like compounds. Finally, DUBs often display specificity for ubiquitin chains as well as the target 
proteins. Hence, to optimise the likelihood of identifying genuine inhibitors, it is prudent to develop 
bespoke primary screening and secondary assays that recapitulate the most physiological substrate 
and ubiquitin-linkage setting for each DUB. 
 
Despite the above issues, DUBs are fundamentally catalytically-driven proteins with known enzymatic 
functions, and as such present researchers with the opportunity to identify small-molecule inhibitors 
either within the active site or at adjacent allosteric pockets. Indeed, over the past few years there 
has been an increasing rate of progress in successfully screening for and evolving small-molecule DUB 
inhibitors, with the most developed of these now moving towards or into clinical evaluation (for 
examples, see Table 2).  
 
Understanding DUB-substrate interactions 
Understanding the mechanism-of-action of individual DUBs is important when initiating any screening 
and subsequent drug-discovery campaign. DUBs are generally isopeptidases that, in most cases, 
catalyse a proteolytic reaction between a lysine Ɛ side chain and a carboxyl group corresponding to 
the ubiquitin C-terminus209. The last two C-terminal amino acid residues are glycines (Gly75-Gly76) 
that lack side chains, resulting in a narrow linker on either side of the isopeptide bond, which is 
mirrored in a long and narrow DUB catalytic cleft209. Moreover, cysteinyl-protease DUB catalytic 
activity tends to rely on two or three crucial residues comprising a catalytic diad or triad, generally 
constituted by a His side-chain that, by lowering the pKa of the catalytic Cys, leads to a nucleophilic 
attack on the ubiquitin-substrate isopeptide linkage12. Collectively, these properties bring complexity 
to identifying selective small-molecule inhibitors that target DUB catalytic sites and are likely to 
restrict the breadth of series that are suitable for developing potent and selective DUB inhibitors. 
The Proteostasis thiophene pyrimidine-cored USP14 inhibitors are known to bind in the ubiquitin 
pocket and prevent the ubiquitylated substrate binding210. However, the majority of historical and 
current DUB drug-discovery programmes have focused on chemical series that include the provision 
of an active “warhead” that forms a reversible or irreversible covalent adduct with the DUB catalytic 
cysteine. The high reactivity of some of these warheads, which include oxidative, alkylating and 
20 
arylating moieties210, is likely to limit drug selectivity, may hamper the development of acceptable 
pharmacokinetic and pharmacodynamics parameters, and may also pose risks of idiosynchratic 
toxicities in patients.  
 
For this reason, less reactive warheads are being explored that are closely related to warheads utilised 
by non-DUB cysteine protease inhibitors in the clinic. For example, the USP8 inhibitor identified from 
a library of amidomethyl methyl acrylates (Compound 6)211 contains a Michael acceptor group also 
found in Rupintrivir, an inhibitor of rhinovirus 3C protease and a GSK cathepsin C inhibitor210. In 
addition, USP9X inhibitors WP1130 and EOA1342143212 contain a Michael acceptor group similar to 
that found in a Principia Biopharma Bruton’s tyrosine kinase (BTK) inhibitor210. However, these 
examples are few in number, and the compounds are weak DUB inhibitors. Mission Therapeutics has 
discovered covalent active-site series that are ‘drug-like’, unrelated to any previously described DUB 
inhibitor, and which achieve sub-micromolar cell-based potencies and exhibit good oral 
bioavailability123,124,147.  
 
Allosteric regulation: implications 
Most peptidases, including many cysteine proteases, recognise a small linear polypeptide motif and 
cleave either before or after the peptide bond213. DUBs, however, are more complex. Most DUBs, 
cleave an isopeptide linkage between the side-chain of a lysine residue and ubiquitin’s carboxyl-
terminal glycine, with the isopeptide linkage providing specificity and flexibility to the mechanism of 
proteolysis214. Also, DUBs need to accommodate a substantial globular post-translational modification 
(ubiquitin, Ubl, or ubiquitin/Ubl chains) into their catalytic site215. Furthermore, unlike most other 
cysteine peptidases, the catalytic triad of cysteinyl peptidase DUBs is not usually in a “functional” 
configuration, with allosteric regulation being required to render DUBs fully functional and processive. 
Such allosteric regulation can be substrate-mediated (e.g. OTULIN)181, triggered by intra-molecular 
reorganisation (e.g. USP7)216 or induced by key cofactors (as for USP1)74. In addition, several DUBs are 
associated with multi-protein complexes such as the proteasome217, p97/VCP218, or the COP9 
signalosome219. These associations can allosterically regulate the affinity of DUBs for their 
substrates208,220 and in some instances DUBs coexist in the same complex as the ubiquitylation 
machinery221. The above issues must therefore be carefully considered when establishing screening 
and compound-evaluation assays for a DUB. Some DUB inhibitors have been suggested to target 
allosteric sites, such as the USP1 inhibitor ML32378. 
 
Screening technologies  
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Approximately twenty years ago, a general assay was established for measuring DUB enzyme activity 
based on the substrate, ubiquitin C-terminal 7-amido-4-methylcoumarin (Ub-AMC). This substrate is 
efficiently cleaved/hydrolysed by various DUBs, releasing a highly fluorescent AMC moiety. While this 
assay has been used in various DUB inhibitor screens, for example to identify USP1222 and USP7207,223,224 
inhibitors, one significant drawback is that it is prone to fluorescence interference exhibited by many 
small molecules225. Moreover, AMC and alternative tags such as Rhodamine and TAMRA, which have 
been employed because they are less prone to fluorescence artefacts, contain a peptide linkage and 
thus differ quite significantly from most natural DUB substrates. Processing of such substrates thus 
requires the DUB to function in a non-physiological manner, thereby potentially diminishing prospects 
for identifying compounds that will operate in cellular or therapeutic settings. 
 
A further challenge for development of DUB inhibitor screening assays is oxidative hydrolysis of the 
active-site cysteinyl residue of purified DUBs in biochemical buffers. This sensitivity requires use of 
protective reducing agents such as dithiothreitol (DTT), usually in millimolar concentrations, to 
maintain DUB enzymatic activity. Altering the concentration or type of reducing agent (for example, 
2-mercaptoethanol, cysteine, glutathione or TCEP) can considerably affect inhibition obtained for hit 
compounds207.  Following a high-throughput screen to identify USP7 inhibitors, Wrigley et al., (2011) 
evaluated the ability of compounds to inhibit USP7 in the presence of different reductants207. Many 
compounds showed the greatest inhibition in the absence of any reductant, being less potent in the 
presence of cysteine or glutathione, and least potent in the presence of DTT or TCEP. A further subset 
of molecules showed an alternative profile, only demonstrating inhibition in the presence of DTT or 
TCEP. A final set of molecules only inhibited USP7 when no additional reductant was added. Together, 
these data demonstrate the critical nature of the reducing environment on DUB activity and inhibition. 
Thus, most screens based on high concentrations of reducing agents and using first-generation 
fluorescent substrates generate high false-positive rates, an issue that has likely been the most 
significant challenge in identifying genuine and selective DUB inhibitors. 
 
Indeed, the non-selective nature of some DUB inhibitors is highlighted in biochemical selectivity-
profiling assays, with relatively few DUB inhibitors reported in the literature showing promise in such 
studies76.  Ritorto et al., (2014) used MALDI-TOF mass spectrometry to screen for DUB activity and 
specificity, by systematically assessing the specificities of 42 recombinant human DUBs against di-
ubiquitin isomers with all possible chain linkages (M1/linear, K6, K11, K27, K29, K33, K48 and K63-
linked)76. Subsequently, they screened a panel of 32 DUBs against nine reported DUB inhibitors. Their 
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findings demonstrated that none of the compounds displayed strong selectivity towards a single DUB, 
and that many inhibited most DUBs on the panel. 
 
Novel technologies based on chemically-synthesised DUB substrates containing isopeptide linkages, 
ubiquitin chains and/or assay technologies less prone to false positives such as luminescence, time-
resolved fluorescence or mass spectrometry are advancing screening campaigns and therefore now 
being exploited76,226-228. For example, a ubiquitin-aminoluciferin substrate was used with a variety of 
DUBs to demonstrate a suitable assay window for high-throughput screening207,229.  Subsequently, 
USP2 was used as a representative DUB to demonstrate statistical robustness of this reagent in a 
screening campaign for inhibitors. We believe that such developments are crucial to optimise the 
prospects for identifying and developing DUB inhibitors for ultimate clinical use. 
 
Monitoring DUB activity/inhibition 
A key issue when studying DUBs and their modulation, in cells, is understanding substrate specificity. 
Some DUBs have preferences for mono-ubiquitylated substrates, while others favour specific 
ubiquitin chain-types, chains bearing mixed linkages, or mixed chains containing ubiquitin and 
Ubls230,231. Furthermore, many DUBs have some specificity for the substrate protein itself, with this 
being mediated through mechanisms often involving regions of the DUB distinct from its catalytic site. 
DUB substrates can be determined by biochemistry, yeast-2-hybrid interactions, proteomic profiling 
and genetics232, but this is often challenging and time-consuming. Clearly, the ability to directly 
monitor DUB activity within a native biological system is essential to understanding the physiological 
and pathological role of individual DUBs as well as the effects of DUB inhibition233. 
 
DUB activity in cells can be monitored by chemical probes that generate readily detectable covalent 
complexes with the DUB catalytic site (recently reviewed in Hewings et al., 2017)234. Activity probes 
label DUBs based on their catalytic site thiol group235, with DUB reactivity towards such probes 
depending on the type of electrophilic warhead fused to ubiquitin. In addition to profiling DUB 
levels/activity and catalytic inhibition, activity probes have also been used to identify DUBs by affinity 
purification/mass spectrometry236. More recently, activity-based probes (ABPs) bearing a fluorescent 
reporter tag have been generated to replace the initial tags (e.g. the HA epitope) to allow fluorescent 
imaging instead of detection by immunoblotting226,227. While production of ubiquitin ABPs was 
historically based on a trypsin-catalysed transpeptidation to modify ubiquitin at its carboxy terminus 
with a vinyl sulfone group, recent approaches involve the full-chemical synthesis of ubiquitin 
ABPs226,237. This advance allows incorporation of modified amino acid residues at any position in the 
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ABPs, whether natural or not. Mass spectrometry has become an important tool to monitor ubiquitin 
adducts as well as changes in ubiquitin levels232,238. Indeed, combining ABPs with immunoblotting or 
mass spectrometry can generate powerful tools for monitoring DUB activity and inhibition by small 
molecules98,239 as well as assessing drug-enzyme target engagement in cells or tissues. For example, 
Altun et al. (2011), used ABPs to demonstrate the selectivity of P22077 for USP7 in cells, in contrast 
to PR-619 which inhibited a broad range of DUBs239. In addition, Reverdy et al., (2012) demonstrated 
the cellular selectivity of HBX19818 for USP7 against a panel of DUBs using ABPs and 
immunoblotting98.  
 
Activity-based proteomic probes have facilitated the development of pharmacologically active 
enzyme inhibitors.  This approach represents a cell-based assay in which treatment with the inhibitor 
is performed on intact cells, allowing for a range of cellular enzymes to be assessed simultaneously239. 
Competition assays between an inhibitor and the ABP lead to a reduced labelling profile for the ABP, 
with loss of signal for ABP-labelled target enzymes allowing assessment of the specificity of inhibition. 
The limitation to this approach, however, is the number of enzymes successfully labelled by the ABP 
and the representation of active enzymes in the cellular proteome. ABPs were used to characterise 
the DUB inhibitors PR-619 and P22077 by immunoprecipitation combined with identification and 
label-free quantification by mass spectrometry based proteomics239. Using this approach, quantitative 
data for 25 cellular DUBs was obtained. PR-619 was confirmed as a broad DUB inhibitor, whereas 
P22077 was found to be a selective inhibitor of USP7 and USP47 that may therefore provide the basis 
for exploring therapeutic opportunities in oncology (see preceding sections and Table 2). 
 
Concluding remarks 
During the past decade, we have witnessed dramatic advances in our understanding of DUB functions, 
mechanisms-of-action, regulation and disease linkages. In parallel, there have been major 
improvements in DUB biochemical assays and screening technologies, leading to the development of 
increasing numbers of small-molecule DUB inhibitors whose selectivity is now being explored, and 
where possible refined. Such inhibitors are providing the basis for drug-like molecules suitable for 
clinical evaluation and are also providing versatile tools to further investigate DUB cell biology, 
regulation and biochemical mechanisms, as well as to test therapeutic hypotheses in disease models. 
Although still too early to predict the extent DUBs will deliver on their broad therapeutic potential, 
the next few years certainly seem set to produce further exciting developments in the arenas of DUB 
biology and drug-discovery. 
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Figure legends 
Figure 1. The ubiquitylation cascade and the deubiquitylase family of proteins. a, Schematic of key 
events in ubiquitylation and deubiquitylation. The E1 enzyme activates ubiquitin in an ATP-
dependent manner, resulting in a covalent thioester linkage between ubiquitin and the E1 cysteine 
residue. Ubiquitin is then transferred to an E2 conjugating enzyme forming a thioester linkage with 
the catalytic cysteine. Finally, an E3 ligase mediates transfer of ubiquitin from the E2 to a substrate, 
usually via a lysine side-chain. In subsequent rounds, ubiquitin molecules can be conjugated to the N-
terminal amino group or lysines on ubiquitin itself to form chains. DUBs remove ubiquitin molecules 
from substrates or process ubiquitin precursors to generate free ubiquitin pools. 
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b, DUB phylogenetic tree. Sequences for full-length DUB and SENP proteins were aligned with 
COBALT, a constraint based alignment tool for multiple protein sequences, and subsequently 
visualised with FigTree v1.4.3. 
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Figure 2.  Various roles of DUBs in oncology. Selected, representative examples of DUBs (light blue 
ovals) involved in distinct cellular pathways and regulation of various ubiquitylated substrates (dark 
blue boxes) related to oncology. The proteasome and associated DUBs facilitate protein turnover and 
recycle ubiquitin. USP28 regulates turnover of the oncogene product c-Myc, ATXN3 controls stability 
of the tumour suppressor p53, and USP7 regulates p53 and its E3 ubiquitin ligase HDM2. USP1, USP4 
and USP11 have important roles in DNA damage repair, while USP9X regulates CLASPIN and is linked 
to replication stress and checkpoint signalling. BAP1 and USP22 participate in chromatin remodelling 
by deubiquitylating histones, and UCHL1 plays a role in AKT signalling. These are representative 
examples only and not meant to be exhaustive. Examples of small-molecule compounds targeting 
these DUBs are shown. 
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Table 1.  DUBs associated with human disease.   
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Table 2.  DUB inhibitors in development.  Chemical structures shown are representative only, and 
additional structures can be found in Kemp, 2016210. 
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